|
Listen now
Getting your Trinity Audio player ready...
|
Emzor Pharmaceutical Industries Limited revenue grew by an annualised rate of 34% to N51.3 billion in the nine-month period ending 30 September 2025 (9M 2025), however an upcoming maturity of outstanding bonds poses risks to its balance sheet.
The growth trajectory has been supported by inflation-led price reviews, higher sales volume and an expanding product portfolio.
Additionally, the exit of multinational pharmaceutical companies from the Nigerian market has created significant opportunities for local manufacturers to capture additional market share.
Revenue also rose by 24.1% to N51.1 billion (USD33.7 million) in the financial year ended 31 December 2024, well above the 7.1% and 9.6% growth rates recorded in 2022 and 2023, respectively.
The primary financial challenge Emzor faces is the upcoming repayment obligation of its N13.729 billion bond maturing on January, 26, 2026.
While the N51 billion revenue figure for 9M suggests strong operational cash flow, repaying a N13.7 billion maturity in a month requires significant liquid funds. The risk lies in how the company plans to fund the repayment:
The group’s intention is to refinance the facility and short-term bridged financing is being negotiated to cover the redemption at an elevated interest margin.
The company may also choose to issue a new bond or Commercial Paper (CP) to refinance the maturing debt, but this depends on the interest rate environment. It may also rely in part on internal cash flow.
Current liquidity sources for Emzor comprise a cash balance of N1.8 billion as of 30 September 2025 and projected operating cash flows of N6.3 billion. However, high capital spending is expected due to ongoing capacity expansion.
Emzor has been investing heavily in local Active Pharmaceutical Ingredients (API) production—a $23 million transformative investment—which is expected to reduce import reliance and potentially improve margins long-term.
Supported by increasing focus on higher-margin products, and better cost optimisation, Emzor’s EBITDA margin widened to 18.8% in 2024, and further to 20.7% in 9M 2025.
Accordingly, operating profit jumped to N7.8 billion in 2024 and N9.4 billion in 9M 2025, from just N1.2 billion in 2023. Significantly, there was a return to net profit in 9M 2025, following three years of net losses, negatively impacted by rising finance charges and foreign exchange losses.
“We expect sustained earnings growth over the outlook period bolstered by higher volumes and the introduction of new drug formulations, with revenue projected to grow by about 40% and 30% for full year 2025 and 2026, respectively. We also forecast an EBITDA margin of around 20% over the next two years, bolstered by increased contributions from higher-margin medicines, enhanced cost efficiency, stable currency and cost savings from VAT and duty waivers on pharmaceutical imports,’ analysts at GCR ratings said.
Gross debt increased to N44.2 billion in 2024 due to new facilities and adverse currency movements on the foreign-denominated loans.
Emzor’s competitive position is underpinned by its solid market position as a manufacturer of about 200 drug formulations under 16 therapeutic categories, with well-established brands leading key generic segments.
The group’s broad market reach is supported by an extensive distribution network of over 160 distributors across Nigeria and Sub-Saharan Africa.
Furthermore, it maintains relationships with international suppliers and technical partnerships with global pharmaceutical players, supporting supply chain stability and product development.
As part of its backward integration plan, the group commenced the construction of Nigeria’s first anti-malarial active pharmaceutical ingredient (API) manufacturing plant in 2021.
However, due to funding constraints and regulatory bottlenecks, progress has stalled, with project completion under 50%. Once completed, the project is expected to strengthen Emzor’s market position and reduce its reliance on imported APIs for production.
Emzor raised N13.729Bn in Series 1 Bond in January 2021 through a special purpose vehicle, Emzor Pharma Funding SPV Plc.
The principal will be fully redeemed at the maturity date through a bullet payment on 26 January 2026, but interest is payable semi-annually.
Follow the MoneyCentral Nigeria channel on WhatsApp: Click here!
